» Articles » PMID: 38478091

HLA Class I NK-epitopes and KIR Diversities in Patients with Multiple Myeloma

Overview
Journal Immunogenetics
Date 2024 Mar 13
PMID 38478091
Authors
Affiliations
Soon will be listed here.
Abstract

Multiple myeloma (MM) is a hematological malignancy caused by the clonal expansion of malignant plasma cells in the bone marrow. Myeloma cells are susceptible to killing by natural killer (NK) cells, but NK cells fail to control disease progression, suggesting immunosuppression. The activation threshold of NK-effector function is regulated by interaction between KIRs and self-HLA class I, during a process called "education" to ensure self-tolerance. NK cells can respond to diseased cells based on the absence of HLA class I expression ("Missing-self" hypothesis). The HLA and KIR repertoire is extremely diverse; thus, the present study aimed to characterize potential variances in genotypic composition of HLA Class I NK-epitopes and KIRs between MM patients and healthy controls. Genotypic expression of KIR and HLA (HLA-C group-C1/C2 and Bw4 motifs (including HLA-A*23, A*24, A*32) were analyzed in 172 MM patients and 195 healthy controls. Compared to healthy controls, we did not observe specific KIR genes or genotypes, or HLA NK-epitopes with higher prevalence among MM patients. The presence of all three HLA NK-epitopes (C1C2Bw4) was not associated with MM occurrence. However, MM patients were more likely to be C1/C2/Bw4 (p = 0.049, OR 1.996). In line with this, there was a trend of increased genetic co-occurrence of Bw4 and KIR3DL1 in MM patients (p = 0.05, OR 1.557). Furthermore, MM patients were more likely to genetically express both C2/KIR2DL1 and Bw4/KIR3DL1 (p = 0.019, OR 2.453). Our results reveal an HLA NK-epitope combination that is associated with the occurrence of MM. No specific KIR genotypes were associated with MM.

References
1.
Martinez-Sanchez M, Periago A, Legaz I, Gimeno L, Mrowiec A, Montes-Barqueros N . Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing. Oncoimmunology. 2016; 5(4):e1093721. PMC: 4839374. DOI: 10.1080/2162402X.2015.1093721. View

2.
Ljunggren H, Karre K . In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today. 1990; 11(7):237-44. DOI: 10.1016/0167-5699(90)90097-s. View

3.
Cisneros E, Moraru M, Gomez-Lozano N, Muntasell A, Lopez-Botet M, Vilches C . Haplotype-Based Analysis of -Gene Profiles in a South European Population-Distribution of Standard and Variant Haplotypes, and Identification of Novel Recombinant Structures. Front Immunol. 2020; 11:440. PMC: 7089957. DOI: 10.3389/fimmu.2020.00440. View

4.
Karre K . Immunology. A perfect mismatch. Science. 2002; 295(5562):2029-31. DOI: 10.1126/science.1070538. View

5.
Bruijnesteijn J, de Groot N, Bontrop R . The Genetic Mechanisms Driving Diversification of the Gene Cluster in Primates. Front Immunol. 2020; 11:582804. PMC: 7516082. DOI: 10.3389/fimmu.2020.582804. View